Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · Real-Time Price · USD
6.56
+0.17 (2.74%)
May 15, 2025, 1:19 PM - Market open
Sage Therapeutics Stock Forecast
Stock Price Forecast
According to 17 professional analysts, the 12-month price target for Sage Therapeutics stock ranges from a low of $4.00 to a high of $26. The average analyst price target of $9.88 forecasts a 50.72% increase in the stock price over the next year.
Price Target: $9.88 (+50.72%)
Analyst Consensus: Hold
* Price targets were last updated on Feb 12, 2025.
Analyst Ratings
The average analyst rating for Sage Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 15 | 15 | 15 | 15 | 14 | 14 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 19 | 20 | 20 | 20 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 30, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Apr 25, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $14 → $12 | Buy | Maintains | $14 → $12 | +83.07% | Feb 12, 2025 |
| Wedbush | Wedbush | Hold Reiterates $6 | Hold | Reiterates | $6 | -8.47% | Feb 12, 2025 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $9 → $8 | Hold | Maintains | $9 → $8 | +22.04% | Feb 12, 2025 |
Financial Forecast
Revenue This Year
84.02M
from 41.24M
Increased by 103.73%
Revenue Next Year
118.08M
from 84.02M
Increased by 40.53%
EPS This Year
-3.58
from -6.59
EPS Next Year
-2.69
from -3.58
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 136.4M | 198.7M | 229.8M | ||
| Avg | 84.0M | 118.1M | 157.8M | ||
| Low | 63.7M | 65.9M | 110.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 230.7% | 136.4% | 94.6% | ||
| Avg | 103.7% | 40.5% | 33.6% | ||
| Low | 54.5% | -21.6% | -6.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.74 | -1.53 | -0.38 | ||
| Avg | -3.58 | -2.69 | -1.62 | ||
| Low | -4.69 | -4.22 | -2.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.